Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors

Masanori Hayashi, David M. Loeb, Allen R. Chen

Research output: Chapter in Book/Report/Conference proceedingChapter


The prognosis for recurrent or refractory pediatric solid tumors such as neuroblastoma, Wilms tumor, rhabdomyosarcoma, retinoblastoma, germ cell tumor, osteosarcoma, and Ewing sarcoma is dismal, and few patients have experienced prolonged survival. Most pediatric solid tumor patients are treated with intensive chemotherapy, and most recurrences occur during treatment or within 1 year of its completion. For agents such as melphalan, carmustine, and carboplatin, whose major dose limiting toxicity is myelosuppression, hematopoietic cell transplantation (HCT) may permit 3-10-fold dose escalation. The recognition that patients with bilateral retinoblastoma are at increased risk of developing osteosarcoma implicates the RB1 gene in the pathogenesis of osteosarcoma. The role of allogeneic HCT in pediatric solid tumors is being explored. Allogeneic transplantation carries the risk of graft-versus-host disease (GVHD), but its potential benefits include the absence of tumor cells in the graft and perhaps an immunologic antitumor effect.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
Number of pages17
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
StatePublished - Jan 1 2016
Externally publishedYes


  • Desmoplastic small round cell tumor
  • Ewing sarcoma
  • Graft-versus-host disease
  • Hematopoietic cell transplantation
  • Neuroblastoma
  • Osteosarcoma
  • Pediatric solid tumors
  • Retinoblastoma
  • Rhabdomyosarcoma
  • Wilms tumor

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Hematopoietic Cell Transplantation for Other Pediatric Solid Tumors'. Together they form a unique fingerprint.

Cite this